Inpp5d-KO Mouse
一般名
Inpp5d-KO
製品ID
S-KO-16385
背景情報
C57BL/6JCya
系統ID
KOCMP-16331-Inpp5d-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Inpp5d-KO Mouse（カタログ番号S-KO-16385）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Inpp5d-KO
系統ID
KOCMP-16331-Inpp5d-B6J-VA
遺伝子名
製品ID
S-KO-16385
遺伝子別名
SHIP, SHIP1, SHIP-1, s-SHIP, SIP-145, p150Ship
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 1
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000169754
NCBIトランスクリプトID
NM_010566
ターゲット領域
Exon 10~17
有効領域の大きさ
~11.6 kb
遺伝子研究の概要
Inpp5d, also known as Inositol polyphosphate-5-phosphatase D, encodes a dual-specificity phosphatase that can dephosphorylate both phospholipids and phosphoproteins. It is a myeloid-expressed gene, and its protein product SHIP1 is an important regulator in microglial phagocytosis, immune response, and phosphoinositide signaling. The NLRP3 inflammasome signaling is one of the associated pathways, and Inpp5d is genetically associated with Alzheimer's disease (AD), highlighting its significance in neurodegenerative disease research [1,2,3,4,5,6,7,8,9,10].
In Inpp5d-deficient mouse models, several important findings have emerged. In the PSAPP mouse model, conditional Inpp5d down-regulation increased plaque burden and the recruitment of microglia to plaques [2]. In the 5xFAD mouse model, Inpp5d haplodeficiency enhanced microglial functions by increasing plaque clearance and preserved cognitive abilities [6]. In the PS19 mouse model of Tauopathy, Inpp5d haplodeficiency alleviated tau pathology and motor deficits [7]. Also, loss of Inpp5d in wild-type mice had sex-specific effects on the brain transcriptome, with affected genes enriched for multiple neurodegeneration terms [8]. In 5xFAD Inpp5dfl/fl Cx3cr1Ert2Cre mice, SHIP-1 deletion in microglia led to enhanced microglial recruitment to Aβ plaques, improved neuronal health, and enhanced plaque containment and Aβ engulfment [10].
In conclusion, Inpp5d is a crucial regulator in microglial-mediated processes, especially in the context of AD-related pathology. Mouse models, including KO/CKO models, have been instrumental in revealing its role in plaque formation, microglial function, and cognitive preservation in AD, as well as in tau pathology. These findings offer potential therapeutic strategies targeting Inpp5d for neurodegenerative diseases.
References:
1. Chou, Vicky, Pearse, Richard V, Aylward, Aimee J, Menon, Vilas, Young-Pearse, Tracy L. 2023. INPP5D regulates inflammasome activation in human microglia. In Nature communications, 14, 7552. doi:10.1038/s41467-023-42819-w. https://pubmed.ncbi.nlm.nih.gov/38016942/
2. Castranio, Emilie L, Hasel, Philip, Haure-Mirande, Jean-Vianney, Liddelow, Shane A, Ehrlich, Michelle E. 2022. Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease. In Alzheimer's & dementia : the journal of the Alzheimer's Association, 19, 2239-2252. doi:10.1002/alz.12821. https://pubmed.ncbi.nlm.nih.gov/36448627/
3. Terzioglu, Gizem, Young-Pearse, Tracy L. 2023. Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer's disease. In Molecular neurodegeneration, 18, 89. doi:10.1186/s13024-023-00674-9. https://pubmed.ncbi.nlm.nih.gov/38017562/
4. Olufunmilayo, Edward O, Holsinger, R M Damian. 2023. INPP5D/SHIP1: Expression, Regulation and Roles in Alzheimer's Disease Pathophysiology. In Genes, 14, . doi:10.3390/genes14101845. https://pubmed.ncbi.nlm.nih.gov/37895194/
5. Chou, Vicky, Fancher, Seeley B, Pearse, Richard V, Menon, Vilas, Young-Pearse, Tracy L. 2023. INPP5D/SHIP1 regulates inflammasome activation in human microglia. In bioRxiv : the preprint server for biology, , . doi:10.1101/2023.02.25.530025. https://pubmed.ncbi.nlm.nih.gov/36865139/
6. Lin, Peter Bor-Chian, Tsai, Andy Po-Yi, Soni, Disha, Lamb, Bruce T, Oblak, Adrian L. 2022. INPP5D deficiency attenuates amyloid pathology in a mouse model of Alzheimer's disease. In Alzheimer's & dementia : the journal of the Alzheimer's Association, 19, 2528-2537. doi:10.1002/alz.12849. https://pubmed.ncbi.nlm.nih.gov/36524682/
7. Soni, Disha M, Lin, Peter Bor-Chian, Lee-Gosselin, Audrey, Chu, Shaoyou, Oblak, Adrian L. 2024. Inpp5d haplodeficiency alleviates tau pathology in the PS19 mouse model of Tauopathy. In Alzheimer's & dementia : the journal of the Alzheimer's Association, 20, 4985-4998. doi:10.1002/alz.14078. https://pubmed.ncbi.nlm.nih.gov/38923171/
8. Dabin, Luke C, Kersey, Holly, Kim, Byungwook, Lamb, Bruce T, Kim, Jungsu. 2024. Loss of Inpp5d has disease-relevant and sex-specific effects on glial transcriptomes. In Alzheimer's & dementia : the journal of the Alzheimer's Association, 20, 5311-5323. doi:10.1002/alz.13901. https://pubmed.ncbi.nlm.nih.gov/38923164/
9. Karch, Celeste M, Goate, Alison M. 2014. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. In Biological psychiatry, 77, 43-51. doi:10.1016/j.biopsych.2014.05.006. https://pubmed.ncbi.nlm.nih.gov/24951455/
10. Samuels, Joshua D, Moore, Katelyn A, Ennerfelt, Hannah E, Price, Richard J, Lukens, John R. 2023. The Alzheimer's disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid beta-mediated pathology. In Alzheimer's & dementia : the journal of the Alzheimer's Association, 19, 4908-4921. doi:10.1002/alz.13089. https://pubmed.ncbi.nlm.nih.gov/37061460/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。